Michael Robert Ballinger

Array ( [id] => 19316877 [patent_doc_number] => 20240238417 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => METHODS OF PRODUCING TUMOR VACCINES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/563241 [patent_app_country] => US [patent_app_date] => 2022-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35675 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -68 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18563241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18019081 [patent_doc_number] => 20220370580 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => CEREBLON-BASED HETERODIMERIZABLE CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/738662 [patent_app_country] => US [patent_app_date] => 2022-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17994 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17738662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19233793 [patent_doc_number] => 20240190985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => THERAPEUTIC CD99 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/555353 [patent_app_country] => US [patent_app_date] => 2022-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28728 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18555353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19235003 [patent_doc_number] => 20240192197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => NOVEL SCREENING SYSTEM FOR DRUG TARGET ANTAGONIST BASED ON CELL LIFE/DEATH PHENOTYPE [patent_app_type] => utility [patent_app_number] => 18/554490 [patent_app_country] => US [patent_app_date] => 2022-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8712 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19186352 [patent_doc_number] => 20240165265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => Pharmaceutical Combinations for Treating Cancer [patent_app_type] => utility [patent_app_number] => 18/551502 [patent_app_country] => US [patent_app_date] => 2022-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51830 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18551502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127195 [patent_doc_number] => 20240132548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => STABILIZED PRE-FUSION RSV FB ANTIGENS [patent_app_type] => utility [patent_app_number] => 18/546798 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17041 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127195 [patent_doc_number] => 20240132548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => STABILIZED PRE-FUSION RSV FB ANTIGENS [patent_app_type] => utility [patent_app_number] => 18/546798 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17041 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830141 [patent_doc_number] => 20220267445 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => Methods and Compositions for Determining Susceptibility to Treatment with Checkpoint Inhibitors [patent_app_type] => utility [patent_app_number] => 17/673602 [patent_app_country] => US [patent_app_date] => 2022-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17673602 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17805779 [patent_doc_number] => 20220257614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => USE OF 12-LIPOXYGENASE INHIBITORS IN THE TREATMENT OF COVID-19 [patent_app_type] => utility [patent_app_number] => 17/672004 [patent_app_country] => US [patent_app_date] => 2022-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5988 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17672004 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748173 [patent_doc_number] => 20220226376 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS [patent_app_type] => utility [patent_app_number] => 17/576866 [patent_app_country] => US [patent_app_date] => 2022-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37760 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17576866 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050956 [patent_doc_number] => 20240092925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => CD5-TARGETING FULLY HUMANIZED ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/261059 [patent_app_country] => US [patent_app_date] => 2022-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8124 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18261059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554883 [patent_doc_number] => 20240366675 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => COMPOSITIONS AND METHODS FOR CD34 GENE MODIFICATION [patent_app_type] => utility [patent_app_number] => 18/269633 [patent_app_country] => US [patent_app_date] => 2021-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34319 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -57 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18269633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953599 [patent_doc_number] => 20240041926 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => DENDRITIC CELL ACTIVATING CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/265498 [patent_app_country] => US [patent_app_date] => 2021-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23907 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18265498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17702853 [patent_doc_number] => 20220202859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => CANCER TREATMENT USING CD38 INHIBITOR AND/OR LENALIDOMIDE AND T-CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 17/559500 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65603 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17559500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17805816 [patent_doc_number] => 20220257651 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => METHODS AND DELIVERY OF ALLOGENEIC CELL PRODUCTS [patent_app_type] => utility [patent_app_number] => 17/559329 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17559329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17822686 [patent_doc_number] => 11427624 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-30 [patent_title] => T cell receptors [patent_app_type] => utility [patent_app_number] => 17/552300 [patent_app_country] => US [patent_app_date] => 2021-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 9 [patent_no_of_words] => 14915 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17552300 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20279444 [patent_doc_number] => 20250304686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-02 [patent_title] => CONDITIONALLY BISPECIFIC BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 18/266848 [patent_app_country] => US [patent_app_date] => 2021-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18266848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955224 [patent_doc_number] => 20240043551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => ANTI-TNFR2 ANTIBODY AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/266600 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21561 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18266600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828406 [patent_doc_number] => 20220265710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA [patent_app_type] => utility [patent_app_number] => 17/540736 [patent_app_country] => US [patent_app_date] => 2021-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28538 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -83 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17540736 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432588 [patent_doc_number] => 20240301086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED COMPOSITIONS, AND METHODS [patent_app_type] => utility [patent_app_number] => 18/255342 [patent_app_country] => US [patent_app_date] => 2021-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57645 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255342 [rel_patent_id] =>[rel_patent_doc_number] =>)